HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Semaglutide lowered MACE 41% within 6 months in SELECT, before major weight loss

Louis Nervegna · May 14, 2025 · ♥ 13 reactions · 14 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Heart attack, stroke & procedures
AI summary & key facts

A Medscape report on new SELECT data: semaglutide (Wegovy) was associated with a 41% lower risk of major adverse cardiovascular events within 6 months of starting, before substantial weight loss or reaching the full 2.4 mg dose. This suggests benefits beyond weight loss.

#glp1HD #selectHD

Research cited

Shared from Medscape · original post

Semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach the full 2.4 mg weekly dose — according to new data from the SELECT trial. Semaglutide May Cut Cardiovascular Risk Before Weight Loss (Medscape)

No photo description available.
← newer: Oat beta-glucan (4 g) cut breakfast glucose peaks 28% and luolder: Centenarians' longevity is tied to genes that lower insulin/ →